Characteristics of patients with AKI-D and controls
| . | AKI-D n (%) . | Controls n (%) . | P value . |
|---|---|---|---|
| No. of patients | 62 | 62 | |
| Age, median (range), y | 58.0 (19.0-71.7) | 54.7 (21.2-77.4) | .235∗ |
| Sex | .472 | ||
| Female | 32 (51.6) | 28 (45.2) | |
| Male | 30 (48.4) | 34 (54.8) | |
| Recipient race | .224 | ||
| White | 54 (87.0) | 57 (91.9) | |
| Black or African American | 4 (6.5) | 0 | |
| Other | 4 (6.5) | 5 (8.1) | |
| Disease | .903 | ||
| Acute leukemia/MDS | 46 (74.2) | 46 (74.2) | |
| Chronic leukemia/MPN | 4 (6.5) | 5 (8.1) | |
| Lymphoma | 9 (14.5) | 8 (12.9) | |
| Plasma cell disorder | 3 (4.8) | 3 (4.8) | |
| Conditioning regimen | .916 | ||
| MAC-TBI | 9 (14.5) | 10 (16.1) | |
| MAC chemotherapy | 17 (27.4) | 19 (30.6) | |
| RIC | 36 (58.1) | 33 (53.2) | |
| Graft source | .563 | ||
| Bone marrow | 10 (16.1) | 6 (9.7) | |
| Peripheral blood stem cells | 51 (82.3) | 54 (87.1) | |
| Umbilical cord blood | 1 (1.6) | 2 (3.2) | |
| GVHD prophylaxis | .002 | ||
| CD34 selection | 1 (1.6) | 3 (4.8) | |
| Posttransplant cyclophosphamide + other(s) | 8 (13.0) | 2 (3.2) | |
| Tacrolimus based | 50 (80.6) | 45 (72.6) | |
| Cyclosporine based | 3 (4.8) | 8 (13.0) | |
| Others | 0 | 4 (6.4) |
| . | AKI-D n (%) . | Controls n (%) . | P value . |
|---|---|---|---|
| No. of patients | 62 | 62 | |
| Age, median (range), y | 58.0 (19.0-71.7) | 54.7 (21.2-77.4) | .235∗ |
| Sex | .472 | ||
| Female | 32 (51.6) | 28 (45.2) | |
| Male | 30 (48.4) | 34 (54.8) | |
| Recipient race | .224 | ||
| White | 54 (87.0) | 57 (91.9) | |
| Black or African American | 4 (6.5) | 0 | |
| Other | 4 (6.5) | 5 (8.1) | |
| Disease | .903 | ||
| Acute leukemia/MDS | 46 (74.2) | 46 (74.2) | |
| Chronic leukemia/MPN | 4 (6.5) | 5 (8.1) | |
| Lymphoma | 9 (14.5) | 8 (12.9) | |
| Plasma cell disorder | 3 (4.8) | 3 (4.8) | |
| Conditioning regimen | .916 | ||
| MAC-TBI | 9 (14.5) | 10 (16.1) | |
| MAC chemotherapy | 17 (27.4) | 19 (30.6) | |
| RIC | 36 (58.1) | 33 (53.2) | |
| Graft source | .563 | ||
| Bone marrow | 10 (16.1) | 6 (9.7) | |
| Peripheral blood stem cells | 51 (82.3) | 54 (87.1) | |
| Umbilical cord blood | 1 (1.6) | 2 (3.2) | |
| GVHD prophylaxis | .002 | ||
| CD34 selection | 1 (1.6) | 3 (4.8) | |
| Posttransplant cyclophosphamide + other(s) | 8 (13.0) | 2 (3.2) | |
| Tacrolimus based | 50 (80.6) | 45 (72.6) | |
| Cyclosporine based | 3 (4.8) | 8 (13.0) | |
| Others | 0 | 4 (6.4) |
MAC, myeloablative conditioning; MAC-TBI, myeloablative conditioning with total body irradiation; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; RIC, reduced-intensity conditioning.
Wilcoxon signed-rank test was used.